Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target

Benzinga Newsdesk www.benzinga.com Negative 89.0%

Neg 89% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben reiterates Sionna Therapeutics (NASDAQ:SION) with a Market Outperform and maintains $63 price target.